- Home
- NEOV vs ADAG Comparison
NEOV vs ADAG Comparison
Compare NEOV & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | ADAG |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | China |
| Employees | 17 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.6M | 146.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEOV | ADAG |
|---|---|---|
| Price | $3.94 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 506.4K | 203.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $150.56 | $3,688.61 |
| Revenue Next Year | $5.31 | $17.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.81 | $1.33 |
| 52 Week High | $7.13 | $4.58 |
Technical Indicators
Market Signals| Indicator | NEOV | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 72.00 |
| Support Level | $3.49 | $1.64 |
| Resistance Level | $4.60 | N/A |
| Average True Range (ATR) | 0.32 | 0.39 |
| MACD | 0.08 | 0.08 |
| Stochastic Oscillator | 88.27 | 70.59 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.